Literature DB >> 20068062

Constitutive activation of caspase-3 and Poly ADP ribose polymerase cleavage in fanconi anemia cells.

Alex Lyakhovich1, Jordi Surrallés.   

Abstract

Fanconi anemia (FA) is a rare syndrome characterized by developmental abnormalities, progressive bone marrow failure, and cancer predisposition. Cells from FA patients exhibit hypersensitivity to DNA cross-linking agents and oxidative stress that may trigger apoptosis. Damage-induced activation of caspases and poly ADP ribose polymerase (PARP) enzymes have been described for some of the FA complementation groups. Here, we show the constitutive activation of caspase-3 and PARP cleavage in the FA cells without exposure to exogenous DNA-damaging factors. These effects can be reversed in the presence of reactive oxygen species scavenger N-acetylcystein. We also show the accumulation of oxidized proteins in FA cells, which is accompanied by the tumor necrosis factor (TNF)-alpha oversecretion and the upregulation of early stress response kinases pERK1/2 and p-P38. Suppression of TNF-alpha secretion by the extracellular signal-regulated kinase inhibitor PD98059 results in reduction of caspase-3 cleavage, suggesting a possible mechanism of caspases-3 activation in FA cells. Thus, the current study is the first evidence demonstrating the damage-independent activation of caspase-3 and PARP in FA cells, which seems to occur through mitogen-activated protein kinase activation and TNF-alpha oversecretion.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20068062     DOI: 10.1158/1541-7786.MCR-09-0373

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  9 in total

1.  Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models.

Authors:  Caroline C Clark; Jeffrey N Weitzel; Timothy R O'Connor
Journal:  Mol Cancer Ther       Date:  2012-07-09       Impact factor: 6.261

2.  Apoptosis induction in lung and prostate cancer cells through silver nanoparticles synthesized from Pinus roxburghii bioactive fraction.

Authors:  Reena Kumari; Adesh K Saini; Amit Kumar; Reena V Saini
Journal:  J Biol Inorg Chem       Date:  2019-10-23       Impact factor: 3.358

3.  Fanconi anemia protein FANCD2 inhibits TRF1 polyADP-ribosylation through tankyrase1-dependent manner.

Authors:  Alex Lyakhovich; Maria Jose Ramirez; Andres Castellanos; Maria Castella; Amanda M Simons; Jeffrey D Parvin; Jordi Surralles
Journal:  Genome Integr       Date:  2011-02-12

4.  Damaged mitochondria in Fanconi anemia - an isolated event or a general phenomenon?

Authors:  Giovanni Pagano; Pavithra Shyamsunder; Rama S Verma; Alex Lyakhovich
Journal:  Oncoscience       Date:  2014-04-21

5.  Utility and Mechanism of SHetA2 and Paclitaxel for Treatment of Endometrial Cancer.

Authors:  Vishal Chandra; Rajani Rai; Doris Mangiaracina Benbrook
Journal:  Cancers (Basel)       Date:  2021-05-12       Impact factor: 6.639

6.  Damaged mitochondria and overproduction of ROS in Fanconi anemia cells.

Authors:  Alex Lyakhovich
Journal:  Rare Dis       Date:  2013-02-20

7.  Baicalein induces cervical cancer apoptosis through the NF-κB signaling pathway.

Authors:  Xiaolan Yu; Yuqing Liu; Yongzhou Wang; Xiguan Mao; Yujiao Zhang; Jiyi Xia
Journal:  Mol Med Rep       Date:  2018-01-25       Impact factor: 2.952

8.  Impaired mitophagy in Fanconi anemia is dependent on mitochondrial fission.

Authors:  Pavithra Shyamsunder; Milan Esner; Maunish Barvalia; Yu Jun Wu; Tomáš Loja; Huat Bay Boon; Matilde E Lleonart; Rama S Verma; Lumir Krejci; Alex Lyakhovich
Journal:  Oncotarget       Date:  2016-09-06

9.  Autophagy-independent induction of LC3B through oxidative stress reveals its non-canonical role in anoikis of ovarian cancer cells.

Authors:  Eswara Murali Satyavarapu; Ranjita Das; Chandan Mandal; Asima Mukhopadhyay; Chitra Mandal
Journal:  Cell Death Dis       Date:  2018-09-17       Impact factor: 8.469

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.